News
Resources
Blog
Sites
Four things to know from IQVIAs latest report
By Katie Koziara | October 29, 2021
As the debate in Washington continues on drug pricing, it’s important that policymakers take into account what is actually happening in the market for medicines. Here are four things about medicine...
Read More
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19 and other diseases
By Douglas Petersen | October 29, 2021
The biopharmaceutical industry has been working tirelessly to develop and manufacture innovative vaccines, therapies and diagnostics to combat COVID-19 and other diseases and illnesses. As of October...
Read More
The patient experience: Insurance design hurdles lead to access issues for too many Americans, including communities of color and the chronically ill.
By Mark Keida | October 28, 2021
3 in 10 insured Americans still face a financial barrier to care and some of the most vulnerable patients are also those more likely to experience barriers in accessing their care, according to our...
Read More
New video: Why changes to the 340B program are essential for patients
By Nicole Longo | October 28, 2021
The 340B program is confusing. That’s a fact that likely no one would question. In fact, it is often forgotten in broader discussions about our health care system even though it is the second largest...
Read More
Making Medicines More Affordable: PhRMA's solutions
By Emilie Signora | October 27, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...
Read More
Guest post: Continued research and development is critical for ALS patients and families
By Guest Contributor | October 25, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...
Read More
The patient experience: Out-of-pocket costs are driving patients affordability and access challenges
By Cynthia Hicks | October 19, 2021
For too many Americans, simply having health insurance isn’t enough to afford and access the care they need. Our inaugural Patient Experience Survey (PES) reveals how rising out-of-pocket costs can...
Read More
Ask About Adherence: CMS finds medication adherence saved Medicare up to $46.6B in avoided health care costs between 2013 and 2018
By Carolyn Ha | October 19, 2021
A recent Centers for Medicare & Medicaid Services (CMS) study found that medication use is improving among seniors and vulnerable beneficiary populations. Better adherence to medicines used to treat...
Read More
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
By Gabby Migliara | October 18, 2021
A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could have if implemented. The economists...
Read More
Strengthening the WTOs global trade and health agenda
By Douglas Petersen | October 18, 2021
The World Trade Organization (WTO) should use the weeks ahead to focus on delivering an ambitious and productive trade and health agenda as it prepares for the Twelfth Ministerial Conference (MC12)...
Read More
New poll shows Americans reject Medicare negotiation once they learn more about the policy
By Cynthia Hicks | October 15, 2021
As the debate in Washington around drug pricing proposals continues to intensify, a new Ipsos/PhRMA poll shows Medicare “negotiation” is not nearly as popular as some might suggest. Survey findings...
Read More
New report: To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and the health system
By Gabby Migliara | October 14, 2021
A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending – depending...
Read More
New analysis adds to research questioning whether 340B is working as Congress intended
By Nicole Longo | October 13, 2021
As the 340B program has grown over the past decade, there has been increased interest in it and ensuring it works in the best interest of patients. Unfortunately, study after study finds that often...
Read More
New report shows more than 260 medicines in development to fight neurodegenerative diseases
By Andrew Powaleny | October 12, 2021
With neurodegenerative diseases affecting millions of individuals in the United States, now is an important time to spotlight the increasing impact these diseases have on our country’s aging...
Read More
What is Kaiser Family Foundation up to?
By Brian Newell | October 12, 2021
For years, Kaiser Family Foundation (Kaiser) has reminded lawmakers that Americans are opposed to government “negotiation” in drug pricing should it lead to less access to medicines and destroy...
Read More
New report shows 3 in 10 Americans that have insurance still face a financial barrier to care
By Katie Koziara | October 7, 2021
Today, we released the results in the first report in a series on patient experiences with the health care system. The report, titled “Barriers to Health Care Access in the Patient Experience,”...
Read More
The important role of antivirals in the fight against COVID-19
By Richard Moscicki, M.D. | October 6, 2021
Throughout the COVID-19 pandemic, public health officials have focused their response into four main areas: 1) rapid and accurate testing: 2) contact tracing systems to monitor outbreaks; 3)...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
